Actively Recruiting
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Led by Hiroshima University Hospital · Updated on 2025-04-30
7
Participants Needed
1
Research Sites
131 weeks
Total Duration
On this page
Sponsors
H
Hiroshima University Hospital
Lead Sponsor
K
Kyoto University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is Phase I/II Dose-Escalation Study to evaluate the tolerability, safety, efficacy and pharmacokinetics of PPMX-T003 in aggressive NK-cell leukemia.
CONDITIONS
Official Title
Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with aggressive NK-cell leukemia based on WHO 2017 criteria, including first-time or recurrent cases
You will not qualify if you...
- Eligible to receive chemotherapy as treatment for aggressive NK-cell leukemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan, 734-8551
Actively Recruiting
Research Team
K
Kiyoshi Ando
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here